IKZF1 deletion + CDKN2A deletion	Acute Myelogenous Leukemia	IKZF1 deletion + CDKN2A deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	IKZF1 deletion + CDKN2B deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion + VPREB1 deletion	Acute Myelogenous Leukemia	IKZF1 deletion + VPREB1 deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 overexpression	Multiple Myeloma	IKZF1 overexpression	Multiple Myeloma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
IKZF1 deletion	Acute Myelogenous Leukemia	IKZF1 deletion	Acute Myelogenous Leukemia	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
IKZF1 deletion	Acute Lymphocytic Leukemia	IKZF1 deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Resistant: C3 – Early Trials dasatinib + blinatumomab Resistant : C3	dasatinib + blinatumomab Resistant: C3 – Early Trials dasatinib + blinatumomab Resistant : C3
TP53 mutation + IKZF1 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation + IKZF1 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
IKZF1 mutation	B Acute Lymphoblastic Leukemia	IKZF1 mutation	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
IKZF1 mutation	Acute Lymphocytic Leukemia	IKZF1 mutation	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
IKZF1 deletion	Acute Lymphocytic Leukemia	IKZF1 deletion	Acute Lymphocytic Leukemia	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3	dasatinib Sensitive: C3 – Early Trials dasatinib Sensitive : C3
IKZF1 deletion + CDKN2B deletion	Acute Lymphocytic Leukemia	IKZF1 deletion + CDKN2B deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
IKZF1 deletion + CDKN2A deletion	Acute Lymphocytic Leukemia	IKZF1 deletion + CDKN2A deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3

IKZF1 (IKAROS Family Zinc Finger 1)

Associations(18)

Associations
(18)